Drugs / Wilate
Wilate
also known as
Optivate · Alphanate · Haemate P · Humate P · Emoclot DI · Factane · Fahndi · Haemoctine SDH · +6 more
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03095287 | Jan 2018 → Sep 2020 | hemophilia A | Grifols Therapeutics LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00717626 | Jul 2008 → Apr 2011 | hemophilia A | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT06205095 | Oct 2024 → Sep 2026 expected | von Willebrand disease (hereditary or acquired) | Unity Health Toronto | Recruiting | No outcome recorded |
| Phase 3 | NCT04953884 | Sep 2021 → Dec 2024 | von Willebrand disease (hereditary or acquired) | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT04052698 | Jun 2020 → Apr 2022 | von Willebrand disease (hereditary or acquired) | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT03376516 | Nov 2017 → Nov 2018 | severe hemophilia A | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT02954575 | Dec 2016 → Mar 2018 | severe hemophilia A | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT01365546 | Jun 2011 → Feb 2014 | — | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT00387192 | Nov 2006 → Sep 2008 | von Willebrand disease (hereditary or acquired) | Bio Products Laboratory | Terminated | No outcome recorded |
| Phase 3 | NCT02246894 | Nov 2003 → Jan 2005 | hemophilia A | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02250482 | Nov 2001 → Aug 2003 | hemophilia A | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 3 | NCT02246881 | Oct 2001 → Jan 2004 | von Willebrand disease (hereditary or acquired) | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04555785 | Apr 2022 → Nov 2027 expected | hemorrhagic disease | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
| Phase 4 | NCT03204539 | Jun 2017 → Jul 2019 | hemophilia A | University of California, Davis | Terminated | No outcome recorded |
| Phase 4 | NCT01811875 | Nov 2014 → Aug 2017 | hemophilia A | Bio Products Laboratory | Terminated | No outcome recorded |
| Phase 4 | NCT00168090 | Oct 2001 → May 2006 | blood platelet disease, von Willebrand disease (hereditary or acquired) | CSL Behring | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01051076 | Nov 2009 → Oct 2020 | severe hemophilia A | City of Hope Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02250508 Comparator | Dec 2004 → Jun 2005 | von Willebrand disease (hereditary or acquired) | Bio Products Laboratory | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01064284 Comparator | Jan 2010 → May 2015 | hemophilia A | Fondazione Angelo Bianchi Bonomi | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01051544 Comparator | Sep 2009 → Jun 2020 | severe hemophilia A | City of Hope Medical Center | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-11-09 | CSL Behring | Patient and Healthcare Provider Convenience Focus of Packaging Enhancements for Humate-P from CSL Behring csl.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Wilate | “Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection.” NCT06205095 ↗9“Human Factor VWF/FVIII Concentrate (Wilate)” NCT01365546 ↗ “Wilate” NCT01051076 ↗ “Wilate” NCT01051544 ↗ |
| Known as | Alphanate | “Alphanate” NCT01051076 ↗ |
| Known as | Antihemophilic Factor/Von Willebrand Factor Complex | “Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von...” NCT00168090 ↗ |
| Known as | Emoclot DI | “Emoclot DI” NCT01051544 ↗1“Emoclot DI” NCT01051076 ↗ |
| Known as | Factane | “Factane” NCT01051544 ↗1“Factane” NCT01051076 ↗ |
| Known as | Fahndi | “Fahndi” NCT01051076 ↗1“Fahndi” NCT01051544 ↗ |
| Known as | Haemate P | “Haemate P” NCT01051076 ↗ |
| Known as | Haemoctine SDH | “Haemoctine SDH” NCT01051544 ↗1“Haemoctine SDH” NCT01051076 ↗ |
| Known as | Human Coagulation Factor VIII | “Optivate® (Human Coagulation Factor VIII)” NCT02250482 ↗ |
| Known as | Human Factor VWF/FVIII Concentrate | “Human Factor VWF/FVIII Concentrate (Wilate)” NCT01365546 ↗ |
| Known as | Humate P | “Humate P” NCT01051076 ↗ |
| Known as | Koate-DVI | “Koate-DVI” NCT01051544 ↗1“Koate-DVI” NCT01051076 ↗ |
| Known as | Octanate | “Octanate” NCT01051076 ↗1“Octanate” NCT01051544 ↗ |
| Known as | Optivate | “Optivate” NCT01051076 ↗ |
| Known as | PLASMA DERIVED Factor VIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01064284 ↗ |
| Action | Restore | “factor VIII replacement” NCT00717626 ↗ |
| Modality | Protein / enzyme biologic | “Blood coagulation Factor VIII and vWF, human” NCT00168090 ↗ |
| Route | Intravenous | “intravenous infusion” NCT01365546 ↗ |